Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

FDA Withdraws Makena Approval Effective Immediately

  • Post author:PacConAdmin
  • Post published:April 6, 2023
  • Post category:Drug Industry Daily

The FDA has withdrawn its approval of Makena, Covis Pharmaceutical’s drug to reduce the risk of pre-term birth in at-risk women, citing the lack of a favorable postmarket benefit-risk assessment…

Continue ReadingFDA Withdraws Makena Approval Effective Immediately

Arbutus, Genevant Allege Patent Infringement Over Pfizer/BioNTech Vaccine Technology

  • Post author:PacConAdmin
  • Post published:April 6, 2023
  • Post category:Drug Industry Daily

Arbutus Biopharma and Genevant Sciences have filed a complaint in a federal court alleging that Pfizer and BioNTech violated five patents related to their messenger RNA (mRNA) delivery technology used…

Continue ReadingArbutus, Genevant Allege Patent Infringement Over Pfizer/BioNTech Vaccine Technology

EMA Adds New Elements to Its PRIME Review Pathway

  • Post author:PacConAdmin
  • Post published:April 6, 2023
  • Post category:Drug Industry Daily

The European Medicines Agency (EMA) is updating its Priority Medicines (PRIME) program to include new ways to track a product’s progress toward approval and to get more timely advice from…

Continue ReadingEMA Adds New Elements to Its PRIME Review Pathway

Double-Check Facts and Understand Observations on Inspection Reports, Expert Advises

  • Post author:PacConAdmin
  • Post published:April 6, 2023
  • Post category:Drug Industry Daily

Double-checking that a Form 483 is factually correct — and that the observations make sense — are two of the most important things a firm can do when given the…

Continue ReadingDouble-Check Facts and Understand Observations on Inspection Reports, Expert Advises

CDER Director Cavazzoni Flags Center’s Priorities for Fiscal 2024

  • Post author:PacConAdmin
  • Post published:April 5, 2023
  • Post category:Drug Industry Daily

Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research (CDER), explained her center’s top budget priorities for fiscal 2024 — highlighting steps to shore up the drug…

Continue ReadingCDER Director Cavazzoni Flags Center’s Priorities for Fiscal 2024

FDA Issues Draft Guidance on Manufacturing Interruptions to Reduce Shortages

  • Post author:PacConAdmin
  • Post published:April 5, 2023
  • Post category:Drug Industry Daily

In a move to help prevent or mitigate shortages, the FDA is asking drugmakers to provide more information regarding manufacturing disruptions that could affect finished drugs and biological products as…

Continue ReadingFDA Issues Draft Guidance on Manufacturing Interruptions to Reduce Shortages

AdvaMed Urges Supreme Court Not to ‘Stifle Innovation’ in Two False Claims Act Cases

  • Post author:PacConAdmin
  • Post published:April 5, 2023
  • Post category:Drug Industry Daily

AdvaMed has submitted an amicus brief to the U.S. Supreme Court in support of two supermarket chains accused of violating the False Claims Act by misreporting their drug prices, arguing…

Continue ReadingAdvaMed Urges Supreme Court Not to ‘Stifle Innovation’ in Two False Claims Act Cases

FDA Enforcement Actions

  • Post author:PacConAdmin
  • Post published:April 5, 2023
  • Post category:Drug Industry Daily

Source: Drug Industry Daily

Continue ReadingFDA Enforcement Actions

Synovo Production Gets Warning Letter for Unreported Modifications

  • Post author:PacConAdmin
  • Post published:April 5, 2023
  • Post category:Drug Industry Daily

The FDA has told Fullerton, Calif.-based Synovo Production to cease manufacture of its hip cup replacement system because the company failed to notify the agency about significant changes to the…

Continue ReadingSynovo Production Gets Warning Letter for Unreported Modifications

Advanced Accelerator Applications Hit With 483 for Deficient Procedures

  • Post author:PacConAdmin
  • Post published:April 5, 2023
  • Post category:Drug Industry Daily

The FDA handed Advanced Accelerator Applications a five-observation Form 483 after conducting an inspection of its Millburn, N.J., facility for failure to establish written procedures for production and process controls…

Continue ReadingAdvanced Accelerator Applications Hit With 483 for Deficient Procedures
  • Go to the previous page
  • 1
  • …
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.